Accueil tpex

Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer

Par un écrivain mystérieux
Last updated 08 juillet 2024
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis - Zhe Jin, Bin Zhang, Lu Zhang
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Frontiers Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review - ScienceDirect
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Biomedicines, Free Full-Text
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era, Journal of Translational Medicine
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
PDF) The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
JCM, Free Full-Text
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Cancers, Free Full-Text
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck - ScienceDirect
Recommandé pour vous
Tu pourrais aussi aimer

© 2014-2024 escolcontabil.com.br. Inc. ou ses affiliés.